Bloom Burton Equities Analysts Raise Earnings Estimates for BioSyent Inc. (CVE:RX)

BioSyent Inc. (CVE:RX) – Investment analysts at Bloom Burton lifted their FY2024 earnings estimates for shares of BioSyent in a research note issued on Monday, September 23rd. Bloom Burton analyst D. Martin now forecasts that the company will earn $0.59 per share for the year, up from their previous estimate of $0.57. The consensus estimate for BioSyent’s current full-year earnings is $0.68 per share. Bloom Burton also issued estimates for BioSyent’s FY2025 earnings at $0.71 EPS and FY2026 earnings at $0.82 EPS.

BioSyent Price Performance

Shares of RX opened at C$11.04 on Wednesday. The company has a 50 day moving average price of C$10.42 and a 200-day moving average price of C$9.54. BioSyent has a fifty-two week low of C$7.75 and a fifty-two week high of C$11.45. The stock has a market capitalization of C$127.95 million, a PE ratio of 18.40 and a beta of 0.93. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13.

BioSyent (CVE:RX) last announced its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share for the quarter, hitting the consensus estimate of C$0.13. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. The firm had revenue of C$8.95 million during the quarter, compared to analysts’ expectations of C$8.80 million.

Insider Transactions at BioSyent

In related news, insider FAX Capital Corp. sold 500,000 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of C$10.05, for a total transaction of C$5,025,000.00. In related news, Director Seyed Ahmad Ashrafi sold 2,320 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of C$10.95, for a total transaction of C$25,404.00. Also, insider FAX Capital Corp. sold 500,000 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of C$10.05, for a total transaction of C$5,025,000.00. In the last quarter, insiders sold 502,920 shares of company stock valued at $5,057,064. Company insiders own 34.21% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.